Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 248353.33%.

  • Lyell Immunopharma's EBIT Margin fell 998092200.0% to 248353.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 836358.54%, marking a year-over-year decrease of 4917299700.0%. This contributed to the annual value of 588122.95% for FY2024, which is 3981168000.0% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's EBIT Margin is 248353.33%, which was down 998092200.0% from 589250.0% recorded in Q2 2025.
  • Lyell Immunopharma's 5-year EBIT Margin high stood at 30.55% for Q4 2022, and its period low was 2214566.67% during Q3 2022.
  • For the 5-year period, Lyell Immunopharma's EBIT Margin averaged around 481716.77%, with its median value being 236156.0% (2023).
  • In the last 5 years, Lyell Immunopharma's EBIT Margin plummeted by 2000000000bps in 2022 and then surged by 2000000000bps in 2023.
  • Over the past 5 years, Lyell Immunopharma's EBIT Margin (Quarter) stood at 1684.55% in 2021, then surged by 98bps to 30.55% in 2022, then crashed by -1498065bps to 457753.85% in 2023, then crashed by -299bps to 1828609.09% in 2024, then skyrocketed by 86bps to 248353.33% in 2025.
  • Its last three reported values are 248353.33% in Q3 2025, 589250.0% for Q2 2025, and 819528.57% during Q1 2025.